1. Home
  2. PHVS vs GNL Comparison

PHVS vs GNL Comparison

Compare PHVS & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • GNL
  • Stock Information
  • Founded
  • PHVS 2015
  • GNL 2011
  • Country
  • PHVS Switzerland
  • GNL United States
  • Employees
  • PHVS N/A
  • GNL N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • GNL Real Estate Investment Trusts
  • Sector
  • PHVS Health Care
  • GNL Real Estate
  • Exchange
  • PHVS Nasdaq
  • GNL Nasdaq
  • Market Cap
  • PHVS 1.6B
  • GNL 1.7B
  • IPO Year
  • PHVS 2021
  • GNL N/A
  • Fundamental
  • Price
  • PHVS $22.08
  • GNL $7.56
  • Analyst Decision
  • PHVS Buy
  • GNL Buy
  • Analyst Count
  • PHVS 6
  • GNL 3
  • Target Price
  • PHVS $36.50
  • GNL $8.67
  • AVG Volume (30 Days)
  • PHVS 217.1K
  • GNL 1.3M
  • Earning Date
  • PHVS 11-12-2025
  • GNL 11-05-2025
  • Dividend Yield
  • PHVS N/A
  • GNL 9.86%
  • EPS Growth
  • PHVS N/A
  • GNL N/A
  • EPS
  • PHVS N/A
  • GNL N/A
  • Revenue
  • PHVS N/A
  • GNL $768,986,000.00
  • Revenue This Year
  • PHVS N/A
  • GNL N/A
  • Revenue Next Year
  • PHVS N/A
  • GNL N/A
  • P/E Ratio
  • PHVS N/A
  • GNL N/A
  • Revenue Growth
  • PHVS N/A
  • GNL 24.38
  • 52 Week Low
  • PHVS $11.51
  • GNL $6.51
  • 52 Week High
  • PHVS $26.33
  • GNL $8.35
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 49.23
  • GNL 44.60
  • Support Level
  • PHVS $22.38
  • GNL $7.62
  • Resistance Level
  • PHVS $23.64
  • GNL $7.73
  • Average True Range (ATR)
  • PHVS 1.28
  • GNL 0.15
  • MACD
  • PHVS 0.04
  • GNL -0.01
  • Stochastic Oscillator
  • PHVS 61.27
  • GNL 44.12

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

Share on Social Networks: